Cyclosporine Interactions: What the Literature Covers on Alcohol, Caffeine, Food and Other Compounds

Why cyclosporine has an unusually large interaction literature

Cyclosporine is a calcineurin inhibitor used across transplantation, dermatology, rheumatology and gastroenterology. A mechanistic review of calcineurin inhibitor disposition described how absorption, distribution and clearance are governed largely by cytochrome P450 3A enzymes and the efflux transporter P-glycoprotein, and framed the resulting between-patient variability as a central clinical determinant (PMID 26912097). Because both the enzyme and the transporter are shared with a very large number of drugs and dietary constituents, researchers have studied cyclosporine co-administration more intensively than most small molecules.

That shared-pathway framework explains the shape of the published record. Where a co-administered compound is itself a strong CYP3A inhibitor or inducer, formal pharmacokinetic studies and dose-adjustment reviews exist. Where a substance is metabolised by a different route — or has simply never been paired with cyclosporine in a controlled study — the literature is silent, and what circulates instead is mechanistic reasoning. This page keeps those two categories visibly separate.

Alcohol and cyclosporine: what the literature in this set does and does not contain

No dedicated alcohol–cyclosporine interaction study appears in the verified citation set for this page. That is a statement about the evidence, not a statement about outcomes. None of the reviews cited here reported a controlled trial in which ethanol was administered alongside cyclosporine and pharmacokinetic or safety endpoints were measured.

Mechanistic reasoning (labelled as such, not as a study finding): the reasoning researchers apply in the absence of direct data starts from the disposition pathways described in the calcineurin inhibitor mechanistic review — first-pass metabolism by intestinal and hepatic CYP3A, plus P-glycoprotein-mediated efflux (PMID 26912097). Ethanol is primarily handled by alcohol dehydrogenase and CYP2E1 rather than CYP3A, so a direct competitive metabolic interaction is not the usual mechanistic concern raised. The concerns that are raised in the general pharmacology literature instead relate to overlapping organ-level effects — hepatic burden and the oral solution formulations of some immunosuppressants that themselves contain ethanol as an excipient. Those are hypotheses about plausibility, not measured interaction data, and this page does not extend them into any recommendation.

Reviews of cyclosporine in dermatology and rheumatology discussed monitoring requirements and the drug's overall tolerability profile as part of long-term use rather than reporting an alcohol-specific experiment (PMID 22859244, PMID 17414949). Readers looking for an alcohol verdict will not find one in the published record summarised here.

Caffeine and cyclosporine

No caffeine–cyclosporine interaction trial appears in this citation set either. Again, this is an evidence gap rather than a finding of absence of effect.

Mechanistic reasoning (labelled as such): caffeine is a well-characterised probe substrate for CYP1A2, whereas the mechanistic review of calcineurin inhibitors located cyclosporine's clearance in the CYP3A/P-glycoprotein system (PMID 26912097). Pharmacologists use that non-overlap to argue that a direct metabolic competition is mechanistically unlikely. No study in this set tested that prediction, so it remains a prediction. Any claim that caffeine measurably raises or lowers cyclosporine exposure would require a pharmacokinetic study that is not present here.

Food, fasting and formulation

Food effects belong to a different evidential category than alcohol and caffeine, because absorption variability is explicitly part of what the disposition literature examined. The mechanistic review addressed the clinical determinants of calcineurin inhibitor absorption and exposure, including the role of intestinal CYP3A and P-glycoprotein at the gut wall, which is the same interface through which meals and dietary constituents act (PMID 26912097). Reviews of clinical use in dermatology likewise discussed the need for exposure monitoring during therapy rather than prescribing a fixed relationship to meals (PMID 22859244).

The practical consequence described in that mechanistic literature is that cyclosporine exposure is sensitive to conditions at the intestinal wall, which is why trough or exposure monitoring, rather than fixed milligram assumptions, dominates the clinical literature (PMID 26912097). This page does not convert that observation into timing instructions of any kind.

Compound combinations that have been formally studied

Azole antifungals

Azoles are the most heavily documented cyclosporine interaction class. A systematic review of dose adjustment of immunosuppressants during co-administration of posaconazole examined published reports of immunosuppressant dosing changes made when posaconazole was added, and researchers compiled those adjustments across the available literature (PMID 29603686). A comprehensive review of drug–drug interactions affecting the pharmacokinetics of isavuconazole examined how co-administered agents alter isavuconazole exposure and how isavuconazole affects partner drugs, including immunosuppressant substrates of CYP3A (PMID 40547223). Both reviews treat the interaction as a managed, measured phenomenon rather than a binary compatible/incompatible question.

Antiviral protease inhibitors

A review of drug–drug interactions with the NS3/4A protease inhibitor simeprevir examined co-administration with transporter and CYP3A substrates and inhibitors, with immunosuppressants among the drug classes the review assessed (PMID 26353895). The study categorised interactions by mechanism — enzyme inhibition and transporter-mediated effects — which is the same framework the calcineurin inhibitor mechanistic review applied (PMID 26912097).

Statins

A pharmacological comparison of the statins examined how the individual agents differ in metabolic route and interaction potential, a distinction researchers use when statins are given alongside CYP3A-dependent immunosuppressants (PMID 14558433). The comparison reported that the statin class is not pharmacokinetically homogeneous, which is why interaction discussions in this area are agent-specific rather than class-wide (PMID 14558433).

Sirolimus

Two perspective reviews on sirolimus described its development and its use in combination immunosuppressive regimens alongside cyclosporine, including the pharmacokinetic interdependence between the two agents that shaped how regimens were constructed (PMID 15859902, PMID 15013304). The ten-year perspective reviewed accumulated clinical experience with sirolimus-based regimens over a decade of transplant practice (PMID 15013304).

Antibiotics — a veterinary example

A 2023 veterinary report described medical management of canine chronic ulcerative stomatitis using cyclosporine together with metronidazole, and researchers reported outcomes of that combined protocol in dogs (PMID 36650996). Species differences in CYP3A activity mean veterinary combination data are not transferable to human pharmacology, and the report is included here only as an example of a studied pairing.

Evidence map: what was actually examined

Interaction-Related Adverse Events: What Studies Report

Reviews of cyclosporine in clinical practice discussed tolerability and monitoring alongside efficacy rather than presenting interactions in isolation. A review of old and new calcineurin inhibitors in lupus nephritis examined the role of these agents in renal disease and addressed the toxicity profile that shapes their use (PMID 34768354). A review of cyclosporine in dermatology likewise discussed monitoring requirements during treatment courses (PMID 22859244), and a review of cyclosporine and tacrolimus in rheumatoid arthritis compared the two calcineurin inhibitors in that setting (PMID 17414949).

In gastroenterology, a review of rescue therapies for steroid-refractory acute severe ulcerative colitis described cyclosporine among the salvage options and compared it with alternative rescue strategies (PMID 36652279). Across these reviews, the recurring theme researchers reported is that exposure control — not fixed dosing — defines how the drug is handled when other agents are present, consistent with the mechanistic account of disposition (PMID 26912097).

How to read an interaction claim about cyclosporine

• Measured versus predicted. A systematic review of posaconazole co-administration compiled actual reported dose adjustments (PMID 29603686); a CYP-pathway argument about caffeine compiles no data at all.
• Direction matters. The simeprevir review distinguished effects on the partner drug from effects on the protease inhibitor itself (PMID 26353895).
• Class is not a unit. The statin comparison reported meaningful differences between individual agents (PMID 14558433).
• Species matters. Canine data on cyclosporine with metronidazole describe a veterinary protocol, not a human one (PMID 36650996).

Educational note

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medication, combination or monitoring question. Nothing here states that any combination is safe, unsafe, advisable or inadvisable — it describes only what the cited studies and reviews examined and reported. Related background is available in the cyclosporine overview.

References

• Clinical determinants of calcineurin inhibitor disposition: a mechanistic review (Drug Metabolism Reviews, 2016)
• Dose adjustment of immunosuppressants during co-administration of posaconazole: a systematic review (Clinical and Investigative Medicine, 2018)
• The Effect of Drug-Drug Interactions on the Pharmacokinetics of Isavuconazole: A Comprehensive Review (Clinical Pharmacology: Advances and Applications, 2025)
• Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir (Clinical Pharmacokinetics, 2016)
• Pharmacological comparison of the statins (Arzneimittel-Forschung, 2003)
• Sirolimus: a current perspective (Experimental and Clinical Transplantation, 2003)
• Sirolimus: a ten-year perspective (Transplantation Proceedings, 2004)
• The use of cyclosporine in dermatology (Journal of Drugs in Dermatology, 2012)
• Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis (Current Opinion in Rheumatology, 2007)
• Old and New Calcineurin Inhibitors in Lupus Nephritis (Journal of Clinical Medicine, 2021)
• Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review (Journal of Crohn's & Colitis, 2023)
• Medical Management of Canine Chronic Ulcerative Stomatitis Using Cyclosporine and Metronidazole (Journal of Veterinary Dentistry, 2023)